NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding NeuBase Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 20 | 1 | 21 | +2 |
| Shares | 347.0K | 15.7K | 460.2K | +128.9K (+38.9%) |
| Value | $301.2K | $13.6K | $340.2K | +$52.6K (+18.3%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 65,724 | $48.6K | 0.00% |
| Renaissance Technologies LLC | 56,967 | $42.0K | 0.00% |
| Two Sigma Investments, LP | 21,083 | $15.6K | 0.00% |
Sold out (1)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Two Sigma Securities, LLC | 12,354 | $10.7K |
Not filed for Q4 2023 yet (1)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Jacob Asset Management of New York LLC | 15,655 | $13.6K |